CO4970816A1 - Combinaciones de estatina-eter carboxialquilico - Google Patents

Combinaciones de estatina-eter carboxialquilico

Info

Publication number
CO4970816A1
CO4970816A1 CO98073828A CO98073828A CO4970816A1 CO 4970816 A1 CO4970816 A1 CO 4970816A1 CO 98073828 A CO98073828 A CO 98073828A CO 98073828 A CO98073828 A CO 98073828A CO 4970816 A1 CO4970816 A1 CO 4970816A1
Authority
CO
Colombia
Prior art keywords
statin
combinations
pharmaceutically acceptable
carboxyalkyl ether
ether
Prior art date
Application number
CO98073828A
Other languages
English (en)
Spanish (es)
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO4970816A1 publication Critical patent/CO4970816A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CO98073828A 1997-12-12 1998-12-11 Combinaciones de estatina-eter carboxialquilico CO4970816A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6937597P 1997-12-12 1997-12-12

Publications (1)

Publication Number Publication Date
CO4970816A1 true CO4970816A1 (es) 2000-11-07

Family

ID=22088573

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98073828A CO4970816A1 (es) 1997-12-12 1998-12-11 Combinaciones de estatina-eter carboxialquilico

Country Status (30)

Country Link
EP (1) EP1045691B1 (enExample)
JP (1) JP2002508320A (enExample)
KR (1) KR20010033003A (enExample)
AR (1) AR017851A1 (enExample)
AT (1) ATE285762T1 (enExample)
AU (1) AU754089B2 (enExample)
BR (1) BR9813542A (enExample)
CA (1) CA2304612A1 (enExample)
CO (1) CO4970816A1 (enExample)
CR (1) CR5926A (enExample)
CU (1) CU20000140A7 (enExample)
DE (1) DE69828442T2 (enExample)
DK (1) DK1045691T3 (enExample)
ES (1) ES2230733T3 (enExample)
GT (1) GT199800196A (enExample)
HN (1) HN1998000185A (enExample)
HU (1) HUP0004547A3 (enExample)
IL (1) IL135349A0 (enExample)
IS (1) IS2150B (enExample)
MY (1) MY118381A (enExample)
NO (1) NO20002966L (enExample)
NZ (1) NZ503982A (enExample)
PA (1) PA8464601A1 (enExample)
PE (1) PE20000017A1 (enExample)
PL (1) PL341066A1 (enExample)
PT (1) PT1045691E (enExample)
SV (1) SV1998000146A (enExample)
UY (1) UY25299A1 (enExample)
WO (1) WO1999030704A1 (enExample)
ZA (1) ZA9811348B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
BR9813539A (pt) * 1997-12-12 2000-10-10 Warner Lambert Co Combinações de inibidor de lp(a) e estatina anti-hiperlipidêmicas
US20030105154A1 (en) 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
BR9914098A (pt) * 1998-09-30 2001-07-31 Warner Lambert Co Método para impedir ou retardar revascularização à base de cateter
US6562864B1 (en) * 1999-09-02 2003-05-13 Drake Larson Catechin multimers as therapeutic drug delivery agents
IN191580B (enExample) * 1999-12-17 2003-12-06 Ranbaxy Lab Ltd
ATE431326T1 (de) 2000-01-25 2009-05-15 Warner Lambert Co Calcium-dicarboxylatether, verfahren zu deren herstellung
AU2001256278A1 (en) * 2000-04-18 2001-10-30 Bayer Aktiengesellschaft Use of cse inhibitors for treating heart failure
PL357906A1 (en) * 2000-04-26 2004-08-09 Warner-Lambert Company Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
US6689807B1 (en) * 2000-06-08 2004-02-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA reductase inhibitors for promoting angiogenesis
JP4188826B2 (ja) * 2001-08-16 2008-12-03 テバ ファーマシューティカル インダストリーズ リミティド カルシウム塩型スタチンの製造方法
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
CN104136023A (zh) 2012-01-06 2014-11-05 密执安生命治疗有限责任公司 降低心血管疾病风险的方法
MX2018005540A (es) 2015-11-06 2018-11-09 Gemphire Therapeutics Inc Tratamiento de dislipemia mixta.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases

Also Published As

Publication number Publication date
AU1591599A (en) 1999-07-05
BR9813542A (pt) 2000-10-10
CA2304612A1 (en) 1999-06-24
NO20002966D0 (no) 2000-06-09
KR20010033003A (ko) 2001-04-25
PE20000017A1 (es) 2000-01-20
EP1045691A1 (en) 2000-10-25
HN1998000185A (es) 1999-06-02
NO20002966L (no) 2000-06-09
PL341066A1 (en) 2001-03-26
HUP0004547A3 (en) 2001-12-28
DE69828442T2 (de) 2005-06-02
CR5926A (es) 2000-03-06
DE69828442D1 (de) 2005-02-03
EP1045691B1 (en) 2004-12-29
SV1998000146A (es) 1999-09-30
PT1045691E (pt) 2005-03-31
UY25299A1 (es) 2001-08-27
GT199800196A (es) 2000-06-03
ATE285762T1 (de) 2005-01-15
NZ503982A (en) 2002-03-28
IL135349A0 (en) 2001-05-20
WO1999030704A1 (en) 1999-06-24
PA8464601A1 (es) 2001-12-14
AR017851A1 (es) 2001-10-24
AU754089B2 (en) 2002-11-07
MY118381A (en) 2004-10-30
DK1045691T3 (da) 2005-03-14
IS5445A (is) 2000-04-14
HUP0004547A2 (hu) 2001-05-28
ES2230733T3 (es) 2005-05-01
ZA9811348B (en) 1999-06-14
CU20000140A7 (es) 2005-10-19
IS2150B (is) 2006-10-13
JP2002508320A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
CO4970816A1 (es) Combinaciones de estatina-eter carboxialquilico
ES2176684T3 (es) Nuevas asociaciones de principios activos que contienen clopidogrel y un antitrombotico.
TR199901077A2 (en) �spen�iyari form�lasyonlar.
IT1255895B (it) Composizioni farmaceutiche contenenti una calcitonina
HUP9900964A3 (en) Protease inhibitors and pharmaceutical compositions containing these compounds
IL138028A0 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical use
AR064896A2 (es) Composicion farmaceutica no higroscopica
ATE293970T1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
FI960032L (fi) Farmaseuttisia koostumuksia vaikeasti liukenevia aktiiviaineita varten
IL109503A0 (en) Hiv protease inhibitors and pharmaceutical compositions containing them
PT981375E (pt) Composicoes farmaceuticas contendo proteinas do plasma
FI965036A7 (fi) Interleukiini-beta:aa muuttavan entsyymin inhibiittoreita sekä niitä sisältävät farmaseuttiset koostumukset
IT8567417A1 (it) Corredo per il confezionamento e l'applicazione di una sostanza, particolarmente per cosmesi, presentantesi in forma solida.
IL135377A0 (en) Pharmaceutical compositions comprising mtp inhibitors
DE69726015D1 (de) Pharmazeutische zusammensetzung enthaltend koenzym q-10
FI955042L (fi) Syklosporiinia sisältävä jauhemainen koostumus
IL122783A0 (en) Cell adhesion inhibitors and pharmaceutical compositions containing the same
FI960849L (fi) Metallikomplekseja sisältäviä farmaseuttisia koostumuksia
ATE231393T1 (de) Flüssige zusammensetzung, hiv protease inhibitoren und c12-c18 fettsaure enthaltend
FI954580A7 (fi) HIV-proteaasin estäjiä farmaseuttisissa yhdistelmissä käytettäväksi AIDSin hoitoon
MA23153A1 (fr) Composition detergente liquide contenant un insecticide
ZA965969B (en) Salts derived from amidine and cyclooxygenase inhibitor process for the preparation thereof their application as medicinal drugs and pharmaceutical compositions in which they are contained
HUP9902256A3 (en) Amidino protease inhibitors and pharmaceutical compositions containing them
FI954986L (fi) Uudet, suun kautta annettavat, syklosporiinia sisältävät farmaseuttiset valmisteet
PT862575E (pt) Novos derivados de geranilgeranilo processo para a sua preparacao e composicoes farmaceuticas relacionadas